China NMPA Drug Inspection - Yabao Pharmaceutical Group Co., Ltd - Mu Xiang Shun Qi Wan

The National Medical Products Administration (NMPA) of China issued an announcement on May 24, 2018, detailing non-compliance issues found in nine batches of drugs produced by six companies. Testing conducted by the Shanxi Provincial Institute for Food and Drug Control and the Jilin Provincial Institute for Drug Control identified significant quality deviations. Specifically, seven batches of peppermint from five companies, including Beijing Tongrentang (Bozhou) Pharmaceutical Co., Ltd., Bozhou Baishixin Traditional Chinese Medicine Pieces Co., Ltd., and Bozhou Yonggang Pharmaceutical Pieces Factory Co., Ltd., failed due to issues with appearance, microscopic characteristics, and thin-layer chromatography. Additionally, one batch of Muxiang Shunqi Pills from Yaodu Pharmaceutical Group Co., Ltd. showed appearance defects, and one batch of Notopterygium incisum from Bozhou Baishixin Traditional Chinese Medicine Pieces Co., Ltd. had a non-compliant characteristic chromatogram. In response, regulatory authorities enacted immediate control measures, including sealing and seizing the affected products. The implicated companies were mandated to suspend sales, recall the non-compliant drugs, and implement corrective actions. The NMPA further directed provincial-level drug regulatory authorities to investigate these enterprises for potential violations of Articles 73, 74, and 75 of the *Drug Administration Law of the People's Republic of China*, related to the production and sale of substandard drugs. Investigations are required to be completed within three months, with the findings publicly disclosed, reinforcing the NMPA's commitment to drug quality and public safety.